Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy
Estudios importantes sobre hipertension arterial de Cuba y el mundo
Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy
Por: Nóra Gullai, Balázs Stenczer, Attila Molvarec, Gergely Fügedi, Zoltán Veresh, Bálint Nagy y János Rigó Jr. Hypertension Research (2013) 36, 457–462; doi.
The aim of this study was to investigate the diagnostic accuracy of the Triage placental growth factor (PlGF) assay, together with its prognostic efficiency in determining the need for preterm delivery in all forms of hypertensive disorders of pregnancy. A total of 130 pregnant women with a diagnosis of preeclampsia (PE: 23), HELLP syndrome (20), superimposed preeclampsia (SIPE: 17), chronic hypertension (CHT: 25), gestational hypertension (GHT: 18) and 27 normotensive pregnant controls were enrolled in this case-control study. A single blood sample was taken between 22 and 34 weeks of gestation, and the plasma was analyzed for PlGF using the Alere Triage PlGF assay. [Actualizado: 29 de julio 2013].
Por: Nobuyuki Miyai, Maki Shiozaki, Mayuko Yabu, Miyoko Utsumi, Ikuharu Morioka, Kazuhisa Miyashita y Mikio Arita. Hypertension Research (2013) 36, 534–539.
Metabolic syndrome (MS) may influence vascular reactivity and might cause an excessive increase in blood pressure (BP) during dynamic exercise. We examined this hypothesis in 698 normotensive men (mean age: 43 years) free of cardiovascular disease, diabetes mellitus and renal disease. The response of BP to exercise was assessed by the mean arterial pressure (MAP) during bicycle ergometry. The MAP values were expressed as z-scores normalized to the relative increases in heart rate. High-normal BP, dyslipidemia and hyperglycemia were diagnosed according to the Japan-specific MS criteria. The z-score of MAP was significantly higher in subjects with high-normal BP (+0.57, P<0.001), dyslipidemia (+0.18, P<0.001) and hyperglycemia (+0.24, P<0.001) than in those without MS component (-0.38). [Actualizado: 29 de julio 2013]
Por: Bassam Farran, Arshad Mohamed Channanath, Kazem Behbehani y Thangavel Alphonse Thanaraj. BMJ Open 2013;3:e002457.
We build classification models and risk assessment tools for diabetes, hypertension and comorbidity using machine-learning algorithms on data from Kuwait. We model the increased proneness in diabetic patients to develop hypertension and vice versa. We ascertain the importance of ethnicity (and natives vs expatriate migrants) and of using regional data in risk assessment. Data on diabetes, hypertension and comorbidity from the cosmopolitan State of Kuwait are available for the first time. This enabled us to apply four different case–control models to assess risks. These tools aid in the preliminary non-intrusive assessment of the population. Ethnicity is seen significant to the predictive models. [Actualizado: 29 de julio 2013].
Por: Mitsuru Ohishi, Tatsuo Kawai, Norihiro Hayashi, Shoichi Kitano, Tomohiro Katsuya, Masahiro Nagano, Atsushi Hirotani, Koichi Yamamoto, Kei Kamide y Hiromi Rakugi. Hypertension Research (2013) 36, 620–626.
Fixed-dose combination (FDC) therapy with telmisartan 40 mg+amlodipine 5 mg (T40/A5) is expected to achieve tight blood pressure (BP) control because of the strong efficacy and long half-life of each drug. The aims of this study were to evaluate the 24-h antihypertensive efficacy of T40/A5 FDC therapy and to explore differences that may arise owing to different administration times in Japanese patients whose hypertension was not controlled by 5 mg of amlodipine per day. In this randomized clinical trial, 44 patients who had been taking amlodipine 5 mg per day and did not achieve their optimal BP target were enrolled (mean age: 67.8±10.2 years). [Actualizado: 24 de julio 2013]
Por: G Bönner, G L Bakris, D Sica, M A Weber, W B White, A Perez, C Cao, A Handley and S Kupfer. Journal of Human Hypertension (2013) 27, 479–486.
Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-converting enzyme inhibitor ramipril (RAM) in patients with clinic systolic blood pressure (SBP) 150–180 mm Hg. Patients were randomised (n=884) to 20 mg AZL-M or 2.5 mg RAM once daily for 2 weeks, then force-titrated to 40 or 80 mg AZL-M or 10 mg RAM for 22 weeks. The primary endpoint was change in trough, seated, clinic SBP. Mean patient age was 57±11 years, 52.4% were male, 99.5% were Caucasian. [Actualizado: 20 de julio 2013].
Comentarios recientes